F. Hoffmann-La Roche had two patents in ecommerce during Q1 2024. The patent filed by F. Hoffmann-La Roche Ltd in Q1 2024 pertains to therapies for the treatment of pathological conditions, particularly cancer, by regulating growth factors in molecular biology. GlobalData’s report on F. Hoffmann-La Roche gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
F. Hoffmann-La Roche grant share with ecommerce as a theme is 50% in Q1 2024. Grant share is based on the ratio of number of grants to total number of patents.
Recent Patents
Application: Combination therapies (Patent ID: US20240046303A1)
The patent filed by F. Hoffmann-La Roche Ltd. pertains to therapies for the treatment of pathological conditions, specifically cancer, by regulating growth factors at the molecular level. The patent outlines a method for extending the duration of response to treatment in patients with BRAFV600 mutation-positive unresectable or metastatic melanoma. This method involves administering specific compositions at specified doses over a 28-day cycle. Additionally, the patent includes a method for delaying or preventing the development of resistance to treatment in similar patients by administering a combination of compositions at specific doses over a 28-day cycle. The patent also includes details about determining the presence of the BRAFV600 mutation and the specific dosages and forms in which the compositions are administered.
The patent further includes claims related to a kit comprising the compositions mentioned earlier, along with a package insert providing instructions for their use in treating patients with BRAFV600 mutation-positive unresectable or metastatic melanoma. The kit is designed to aid healthcare providers in administering the treatment regimen effectively. The patent emphasizes the importance of the specific dosages, administration schedules, and forms of the compositions for optimal therapeutic outcomes in previously untreated patients with metastatic melanoma.
To know more about GlobalData’s detailed insights on F. Hoffmann-La Roche, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
